Last reviewed · How we verify
Human epidermal growth factor 2 negative carcinoma of breast
Approved treatments
- PD-0332991 · Pfizer Inc.
PD-0332991, 125mg, 3 cycles - Verzenio · Eli Lilly
Abemaciclib inhibits CDK4 and CDK6, blocking Rb phosphorylation and G1/S cell cycle progression. - Lynparza · University of Texas Southwestern Medical Center
- Lynparza · AstraZeneca
Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP. - Ibrance · Pfizer
Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Human epidermal growth factor 2 negative carcinoma of breast patent landscape — cliff calendar, originator estates, attackable patents
- Human epidermal growth factor 2 negative carcinoma of breast treatment landscape brief
- Human epidermal growth factor 2 negative carcinoma of breast treatment updates RSS
Frequently asked questions about Human epidermal growth factor 2 negative carcinoma of breast
What drugs treat Human epidermal growth factor 2 negative carcinoma of breast?
Tracked treatments include PD-0332991, Verzenio, Lynparza, Ibrance.
What is the treatment for Human epidermal growth factor 2 negative carcinoma of breast?
Standard treatment for Human epidermal growth factor 2 negative carcinoma of breast includes PD-0332991, Verzenio, Lynparza, Ibrance. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Human epidermal growth factor 2 negative carcinoma of breast patent cliff · Human epidermal growth factor 2 negative carcinoma of breast CI report
- Treatment: PD-0332991 · Pfizer Inc.
- Treatment: Verzenio · Eli Lilly
- Treatment: Lynparza · University of Texas Southwestern Medical Center
- Treatment: Lynparza · AstraZeneca
- Treatment: Ibrance · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing